Post protocol treatment | Sorafenib group (%) | HAIC group (%) |
|---|
Absent | 4 (12) | 17 (49) |
Present | 29 (88) | 18 (51) |
sorafenib continuation | 11 (33) | 10 (29) |
Resection | 0 (0) | 1a (3) |
RFA | 2 (6) | 1b (3) |
TACE | 5 (15) | 5c (14) |
HAIC | 18 (55) | 3 (9) |
Others | 1d (3) | 2e (6) |
- HAIC hepatic arterial infusion chemotherapy, RFA radiofrequency ablation, TACE transarterial chemoembolization; Resection as a conversion option were administered in one patient a, RFA in one b, and TACE in two of five patients c; d, One patient participated in a clinical trial examining tivantinib; e, One patient participated in a clinical trial examining tivantinib and another one received percutaneous ethanol injection treatment (PEIT)
